Gels for encapsulation of biological materials

• US 20040138329A1
• Filed: 12/19/2003
• Published: 07/15/2004
• Est. Priority Date: 04/20/1992
• Status: Abandoned Application

• Current Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Original Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Inventors: Hossainy, Syed F.A., Pathak, Chandrashekhar P., Hill-West, Jennifer L., Sawhney, Amarpreet S., Desai, Neil P., Hubbell, Jeffrey A.
• Application Number:
  US10/743,687
• Publication Number:
  US 20040138329A1
• Time in Patent Office: Days
• US Class Current: 523/114
• CPC Class Codes: A61K 2035/128 capsules, e.g. microcapsules
• CPC Class Codes: A61K 35/30 Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
• CPC Class Codes: A61K 35/39 Pancreas; Islets of Langerhans Langerhans cells of epidermis A61K35/36
• CPC Class Codes: A61K 38/42 Haemoglobins; Myoglobins
• CPC Class Codes: A61K 38/43 Enzymes; Proenzymes; Derivatives thereof
• CPC Class Codes: A61K 9/1635 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61L 24/0031 Hydrogels or hydrocolloids
• CPC Class Codes: A61L 24/046 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds A61L24/043 takes precedence
• CPC Class Codes: A61L 26/0019 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• CPC Class Codes: A61L 29/085 Macromolecular materials
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: C08F 290/00 Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups
• CPC Class Codes: C08F 290/02 on to polymers modified by introduction of unsaturated end groups
• CPC Class Codes: C08F 290/062 Polyethers
• CPC Class Codes: C08L 71/02 Polyalkylene oxides
• CPC Class Codes: C09D 153/00 Coating compositions based on block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Coating compositions based on derivatives of such polymers
• CPC Class Codes: C12N 11/04 entrapped within the carrier, e.g. gel or hollow fibres
• CPC Class Codes: C12N 2533/30 Synthetic polymers thermoreactive polymers, e.g. PNIPAm, C12N2539/10
• CPC Class Codes: C12N 2533/32 Polylysine, polyornithine
• CPC Class Codes: C12N 2533/74 Alginate
• CPC Class Codes: C12N 5/0012 : Cell encapsulation

Abstract

This invention provides novel methods for the formation of biocompatible membranes around biological materials using photopolymerization of water soluble molecules. The membranes can be used as a covering to encapsulate biological materials or biomedical devices, as a “glue” to cause more than one biological substance to adhere together, or as carriers for biologically active species.

Several methods for forming these membranes are provided. Each of these methods utilizes a polymerization system containing water-soluble macromers, species which are at once polymers and macromolecules capable of further polymerization. The macromers are polymerized using a photoinitiator (such as a dye), optionally a cocatalyst, optionally an accelerator, and radiation in the form of visible or long wavelength UV light. The reaction occurs either by suspension polymerization or by interfacial polymerization. The polymer membrane can be formed directly an the surface of the biological material, or it can be formed on material which is already encapsulated.

Claims

1. A crosslinked biocompatible material comprising at least one ionically crosslinked component;

and at least one covalently crosslinked component, wherein the ionically crosslinked component is selected from a polysaccharide, a polyanion, or a polycation.

2. The crosslinked biocompatible material of claim 1 wherein the ionically crosslinked component is alginate.

3. The crosslinked biocompatible material of claim 2 wherein the alginate is a high G block alginate having at least 60% a-L-guluronic acid.

4. The crosslinked biocompatible material of claim 3 wherein the a-L-guluronic acid comprises at least 70% a-L-guluronic acid.

5. The crosslinked biocompatible material of claim 2 further comprising a biologic encapsulated by the material.

6. The crosslinked biocompatible material of claim 5, wherein the material is effective to provide immunoprotection for the biologic in a psychological environment.

7. The crosslinked biocompatible material of claim 6, wherein the material provides immunoprotection of the biologic when xenotransplanted.

8. The crosslinked biocompatible material of claim 5, wherein the biologic is a biologically active materaial or a diagnostic marker.

9. The crosslinked biocompatible material of claim 8, wherein the biologically active materials are living cells selected from islet of Langerhans, dopamine secreting cells, crythropoietin secreting cells, nerve growth factor secreting cells, parathyroid cells, or norepinephrine/-metacephalin secreting cells.

10. The crosslinked biocompatible material of claim 8, wherein the biologically active material is a drug.

11. A crosslinked biocompatible material comprising:

at least one ionically crosslinked component; and

at least one covalently crosslinked component is derived from a polyalkylene oxide.

12. The crosslinked biocompatible material of claim 11, wherein the covalently crosslinked component is polyethylene glycol diacrylate.

13. The crosslinked biocompatible material of claim 11, further comprising a biologic encapsulated by the material.

14. The crosslinked biocompatible material of claim 13, wherein the material is effective to provide immunoprotection for the biologic in a physiological environment.

15. The crosslinked biocompatible material of claim 14, wherein the material provides immunoprotection of the biologic when xenotransplanted.

16. The crosslinked biocompatible material of claim 13, wherein the biologic is a biologically active material or a diagnostic marker.

17. The crosslinked biocompatible material of claim 16, wherein the biologically active materials are living cells selected from the islets of Langherhans, dopamine secreting cells, erythroprotein secreting cells, nerve growth factor secreting cells, hepatocytes, adrenaline/angiotensin secreting cells, parathyroid cells, or norepinephrine/metacephalin secreting cells.

18. The crosslinked biocompatible material of claim 16, wherein the biologically active material is a drug.

19. A crosslinkable biocompatible mixture comprising:

at least one ionically crosslinkable component; and

at least one covalently crosslinkable component, wherein the ionically crosslinkable component is selected from a polysaccharide, a polyanion, or polycation.

20. The crosslinkable biocompatible mixture of claim 19, wherein the ionically crosslinkable component is alginate.

21. The crosslinkable biocompatible mixture of claim 20, wherein the alginate is capable of ionically crosslinking by adding multivalent cations to the mixture.

22. The crosslinkable biocompatible mixture of claim 19, wherein the composition ratio between the ionically crosslinkable component and the covalently crosslinkable component is effective for the stable crosslinking of the mixture, whereby a gelled encapsulation material is formed.

23. The crosslinkable biocompatible mixture of claim 22, wherein the concentration and the molecular weight(s) of the covalently crosslinkable component are effective to provide immunoprotection to the encapsulated functional core once the mixture has been crosslinked.

24. The crosslinkable biocompatible mixture of claim 23, wherein the mixture has an osmolarity and pH compatible with the living tissue or cells.

25. The crosslinkable biocompatible mixture of claim 24, wherein the osmolarity of the mixture is about 290 milliosmoles per kilogram and the pH is about 7.4.

26. The crosslinkable biocompatible mixture of claim 23, wherein the concentration and molecular weight(s) of the covalently crosslinkable component are effective for the controlled release of the biologic or components of the biologic once the mixture has been crosslinked.

27. A crosslinkable biocompatible mixture comprising:

at least one ionically crosslinkable component; and

at least one covalently crosslinkable component, wherein the covalently crosslinkable component is a polyalkylene oxide.

28. The crosslinkable biocompatible mixture of claim 27, wherein the polyalkylene oxide is capable of covalently crosslinking by free radical polymerization.

29. The crosslinkable biocompatible mixture of claim 27, wherein the polyalkylene oxide is polyethylene glycol diacrylate.

30. The crosslinkable biocompatible mixture of claim 27, wherein the composition ratio between the ionically crosslinkable component and the covalently crosslinkable component is effective for the stable crosslinking of the mixture, whereby a gelled encapsulation material is formed.

31. The crosslinkable biocompatible mixture of claim 30, wherien the concentrator, and the molecular weight(s) of the covalently crosslinkable component are effective to provide immunoprotection to the encapsulated functional core once the mixture has been crosslinked.

32. The crosslinkable biocompatible mixture of claim 31, wherein the mixture has an osmolarity and pH compatible with living tissue or cells.

33. The crosslinkable biocompatible mixture of claim 32, wherein the osmolarity of the mixture is about 290 milliosmoles per kilogram and the pH is about 7.4.

34. The crosslinkable biocompatible mixture of claim 31, wherein the concentration and molecurlar weight(s) of the covalently crosslinkable component are effective for the controlled release of the biologic or components of the biologic once the mixture has been crosslinked.

35. A retrievable implantation material, comprising:

a crosslinked biocompatible macrocapsule comprising at least one ionically crosslinked component, and at least one covalently crosslinked component, whereby said macrocapsule encapsulates s microcapsule(s) of a biologic.

36. The retrievable implantation material of claim 35, wherein the macrocapsule provides immunoprotection to the encapsulated microcapsule(s) or biologic when xenotransplanted.